| dc.contributor.advisor | 于卓民 | zh_TW |
| dc.contributor.advisor | Yu, Chwo Ming | en_US |
| dc.contributor.author (Authors) | 桂儀庭 | zh_TW |
| dc.contributor.author (Authors) | Kui, Yi-Ting | en_US |
| dc.creator (作者) | 桂儀庭 | zh_TW |
| dc.creator (作者) | Kui, Yi-Ting | en_US |
| dc.date (日期) | 2018 | en_US |
| dc.date.accessioned | 10-Jul-2018 15:51:12 (UTC+8) | - |
| dc.date.available | 10-Jul-2018 15:51:12 (UTC+8) | - |
| dc.date.issued (上傳時間) | 10-Jul-2018 15:51:12 (UTC+8) | - |
| dc.identifier (Other Identifiers) | G0106363054 | en_US |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/118569 | - |
| dc.description (描述) | 碩士 | zh_TW |
| dc.description (描述) | 國立政治大學 | zh_TW |
| dc.description (描述) | 企業管理研究所(MBA學位學程) | zh_TW |
| dc.description (描述) | 106363054 | zh_TW |
| dc.description.abstract (摘要) | 本研究為探討國際製藥公司在台灣如何回應專利懸崖之問題，對於六家國際大藥廠共十項藥物（個案）進行訪談，在研究分析後提出解釋與觀察。根據過去文獻指出，藥廠面臨專利懸崖之因應策略可分為：預防型、創新型、萃取型與適應型等四種類型，然而，經本研究分析後發現，新增“差異型”與“兌現型”策略，“差異型策略”適用在藥品生命週期之中後期，利用各種手段強調原廠藥與仿製之不同;“兌現型策略”適用在蛋白質藥物等需高技術之藥品，為公司層面之策略。此外，對於藥品生命週期管理，七成藥物會採取預防或創新策略，四成藥物會採取差異型策略。若將藥物分別就癌症（重大疾病）與非癌症（非重大疾病）類別進行分類後發現，癌症藥品傾向中後期之策略實施與佈局，企圖延續市場價值;非癌症藥物則傾向早中期之預防與創新策略佈局，對藥物進行保護。 | zh_TW |
| dc.description.abstract (摘要) | This study explores how international pharmaceutical companies respond to the patent cliff in Taiwan by conducting interviews with a total of 10 drug cases from six international pharmaceutical companies to provide explanations and observations after analysis. According to previous studies, there are four types of strategies in patent cliff research: prevention, innovation, extraction, and adaption. However, this study discovered two new strategies called differentiation and cash-out. The strategy of differentiation applies to the later stages of a drug’s life cycle and emphasizes the differences between the patented drugs and the generic drugs. On the other hand, cash-out strategy requires high technologies, such as protein drugs, to quickly sell markets and technologies through mergers and acquisitions by another company. In drug life cycle management, 70% of drugs adopt preventive or innovative strategies and 40% of drugs adopt differentiation strategies. If drugs are separately classified into the cancer (major disease) and non-cancer (non-major disease) categories, cancer drugs are implemented via differentiation and extraction strategies in the mid-to-late stages and attempt to extend their market value, whereas non-cancer drugs implement prevention and innovation strategies in the early- and mid-term stages. | en_US |
| dc.description.tableofcontents | 第一章 緒論 1 第一節 研究背景與動機 1 第二節 研究問題與目的 3 第三節 研究流程與章節簡介 5 第二章 原廠藥面對專利懸崖之因應策略 7 第三章 台灣藥業市場分析 16 第一節 台灣藥物市場規範 16 第二節 台灣健保署規範 19 第四章 研究方法 23 第一節 研究架構 23 第二節 研究方法與資料搜集 24 第五章 個案資料描述與分析 26 第一節 國際藥廠規模與產品線 27 第二節 藥物分類與台灣市場藥物需求 30 第三節 個案資料描述 32 第四節 個案資料分析 35 第五節 綜合分析與比較 42 第六章 結論與建議 48 第一節 研究結論 48 第二節 管理意涵 49 第三節 研究限制與未來研究建議 50 參考文獻 52 | zh_TW |
| dc.source.uri (資料來源) | http://thesis.lib.nccu.edu.tw/record/#G0106363054 | en_US |
| dc.subject (關鍵詞) | 藥廠 | zh_TW |
| dc.subject (關鍵詞) | 專利懸崖 | zh_TW |
| dc.subject (關鍵詞) | 藥品生命週期管理 | zh_TW |
| dc.subject (關鍵詞) | 專利藥品策略 | zh_TW |
| dc.subject (關鍵詞) | Pharmaceutical company | en_US |
| dc.subject (關鍵詞) | Patent cliffs | en_US |
| dc.subject (關鍵詞) | Drugs life cycle management, | en_US |
| dc.subject (關鍵詞) | Patented drug strategies | en_US |
| dc.title (題名) | 藥廠因應專利懸崖策略之研究-外商在台灣之個案 | zh_TW |
| dc.title (題名) | Strategic Responses to Patent Cliffs-The Case of International Pharmaceutical Firms in Taiwan | en_US |
| dc.type (資料類型) | thesis | en_US |
| dc.relation.reference (參考文獻) | 中文文獻 1. 鄧哲明 (2013)，「新藥研發流程概論」，科學月刊 44卷, 188-193。 2. 歐盈全、歐盈如（2013），「新藥臨床試驗簡介」，科學月刊44卷, 207-212。 3. 劉祖惠、許毓真、巫文玲、賴瓊雅、陳怡蓁、寇怡衡（2016），製藥產業年鑑2016, 台北：財團法人生物技術開發中心。 4. 賴瓊雅、巫文玲、陳怡蓁、劉曉君、王意婷、譚中岳、呂雅蕙（2017），2017醫藥產業年鑑, 台北：財團法人生物技術開發中心。 5. 羅淑慧、陳麗敏（2010），藥品再創價值的策略運用與發展趨勢, 台北：經濟部技術處。 英文文獻 1. Agrawal, M. and N. Thakkar (1997). "Surviving patent expiration: strategies for marketing pharmaceutical products." Journal of Product & Brand Management, 6(5): 305-314. 2. Bhat, V. N. (2005). "Patent term extension strategies in the pharmaceutical industry." Pharmaceuticals, Policy and Law, 6(1): 109-122. 3. Brass, E. P. (2001). "Changing the status of drugs from prescription to over-the-counter availability." New England Journal of Medicine, 345(11): 810–816. 4. Burdon, M. and K. Sloper (2003). "The Art of Using Secondary Patents to Improve Protection." Journal of Medical Marketing, 3(3): 226–238. 5. Cantrell, R. (2009). Outpacing the competition: patent-based business strategy. Hoboken, NJ : Wiley. 6. Chandon, P. (2004). "Innovative Marketing Strategies after Patent Expiry: The Case of GSK`s Antibiotic Clamoxyl in France." Journal of Medical Marketing, 4(4): 65-73. 7. Dubey, R. and J. Dubey (2009). "Pharmaceutical Product Differentiation: A Strategy for Strengthening Product Pipeline and Life Cycle Management." Journal of Medical Marketing, 9: 104–118. 8. efpia (2014). The pharmaceutical industry in figures. http://www.efpia.eu/uploads/Figures_2014_Final.pdf. 9. Gilbert, X. and P. Strebel (1987). "Strategies to outpace the competition." Journal of Business Strategy, 8(1): 28-36. 10. Glasgow, L. J. (2001). "Stretching the limits of intellectual property rights: has the pharmaceutical industry gone too far?" The Journal of Law and Technology, 41: 227–258. 11. Grabowski, H. and J. M. Vernon (2000). "Effective Patent Life in Pharmaceuticals." International Journal of Technology Management, 19: 98–120. 12. Haffner ME and Torrent-Farnell J and Maher PD (2008). "Does orphan drug legislation really answer the needs of patients?" Lancet, 371: 2041–2044. 13. Hutchins, M. (2003). "Extending the Monopoly – How ‘Secondary Patents’ Can Be Used to Delay or Prevent Generic Competition upon Expiry of the Basic Product Patent." Journal of Generic Medicines, 1(1): 57-71. 14. Mittra, J. (2007). "Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms." Technology Analysis & Strategic Management, 19(3): 279-301. 15. Mittra, J. and J. Tait (2012). "Analysing stratified medicine business models and value systems: innovation-regulation interactions." New Biotechnology, 29: 709–719. 16. Raasch, C. (2008). "Launching a Fighter Brand to Cushion Patent Expiry: The Case of Zocor." Journal of Medical Marketing, 8(2): 119-126. 17. Raasch, C. (2009). "Strategic options to tackle patent expiration: theoretical framework and case studies." International Journal of Intellectual Property Management, 3: 278–300. 18. Song, C. H. and J.-W. Han (2016). "Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry." Springerplus, 5(1): 692. 19. Waterschoot, W. v. and C. v. d. Bulte (1992). "The 4P Classification of the Marketing Mix Revisited." Journal of Marketing, 56(4): 83-93. | zh_TW |
| dc.identifier.doi (DOI) | 10.6814/THE.NCCU.MBA.028.2018.F08 | - |
